Once operations resumed, decrease seen in new patients screened, proportion of suspicious nodules increased
Pulmonary complication, postoperative SARS-CoV-2 infection rates lower with COVID-19-free pathways
Use of ACE-I/ARB versus nonuse linked to lower mortality for those hospitalized with flu, pneumonia
No infection identified among surgeons following procedure; postoperative complications rarely seen
However, no significant difference in mortality found between remdesivir and placebo groups
No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir
If enough people in the U.S. pass on vaccine, the nation may not be able to achieve herd immunity
No clinical benefit seen versus placebo for hospital-based health care workers exposed to patients with COVID-19
Higher case fatality rates found to be independent of demographic factors, such as age, sex, and race
Agency says it is especially true in enclosed spaces with inadequate ventilation